Particle Sciences to acquire HORIBA's Raman/Particle Characterization System

NewsGuard 100/100 Score

Particle Sciences Inc. (PSI), a leading pharmaceutical CRO, is adding to its formulation and characterization abilities through a cooperative agreement with HORIBA Scientific. Under the agreement Particle Sciences will acquire a HORIBA Raman/Particle Characterization System.

This multimodal imaging system is a breakthrough apparatus that combines the chemical selectivity of Raman spectroscopy with particle size and morphology characterization from Clemex Technologies, Inc. According to Dr. Robert Lee (VP, Pharmaceutical Development at PSI), "Particle Sciences works extensively with combination products and other formulation systems where precise location of the API and its particle size are of critical importance. This new device will enable us to approach this question with a robust and validatable system." According to Dr. Andrew Whitley (VP, Sales at HORIBA), "We are confident that PSI, with its broad range of challenging products, will be a tremendous asset in demonstrating the unique characterization capabilities enabled by combining the two powerful techniques of particle analysis and Raman chemical imaging in a single system."

Under the arrangement, Particle Sciences will acquire the HORIBA Raman/Particle Characterization System with guaranteed hardware and software upgrades as and when they become available. The two companies will also work together on application and method development. Dr. Lee states that, "Since this is an important area for us, we are very happy to get the system in house at this early stage." From HORIBA's perspective, "Particle Sciences is a leader in particulate formulations in both semisolids and devices. Having their input in the final product will help us ensure we provide our customers with the greatest utility and most useful interface possible," adds Dr. Whitley.

SOURCE Particle Sciences Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New machine learning model achieves breakthrough in heart disease prediction with over 95% accuracy